<DOC>
	<DOCNO>NCT00790114</DOCNO>
	<brief_summary>To determine effect repeat dos AZD7325 pharmacokinetic profile CYP3A4 substrate ( midazolam 1 ' hydroxy metabolite ) CYP1A2 substrate ( caffeine paraxanthine [ 3-desmethyl ] metabolite ) .</brief_summary>
	<brief_title>Determine Effect Multiple Doses AZD7325 , CYP Study</brief_title>
	<detailed_description />
	<mesh_term>Caffeine</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Clinically relevant abnormality physical examination , vital sign , clinical chemistry , hematology urinalysis judge investigator and/or sponsor . Enrollment another concurrent investigational study intake investigational drug within 3 month intake investigational drug within period 5 half life drug prior screen visit</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Phase I</keyword>
</DOC>